Ignite Creation Date:
2024-05-06 @ 4:29 PM
Last Modification Date:
2024-10-26 @ 2:11 PM
Study NCT ID:
NCT05009030
Status:
COMPLETED
Last Update Posted:
2022-07-29
First Post:
2021-08-10
Brief Title:
Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients
Sponsor:
Fundación GECP
Organization:
Fundación GECP
Study Overview
Official Title:
Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VAC-CaP
Brief Summary:
Observational and multicenter retrospective study of data collection in hospital centers throughout the Spanish geography
This study aims to be nationwide in order to study general common variables of the patients as well as the correlation with the cancer treatments received
This study aims to be nationwide in order to study general common variables of the patients as well as the correlation with the cancer treatments received
Detailed Description:
Observational and multicenter retrospective study of data collection in hospital centers throughout the Spanish geography
This study aims to be nationwide in order to study general common variables of the patients as well as the correlation with the cancer treatments received
Disease and study population Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19
The study will be extended to all the centers of the Spanish Lung Cancer Group more than 170 centers and 500 professionals and it is expected that around 500 cases will be collected
The main objective of the study is to collect the safety and efficacy of the vaccine against SARS-CoV-2 in cancer patients as well as its potential interactions with antineoplastic therapies
The data collection will take place throughout the year 2021
This study aims to be nationwide in order to study general common variables of the patients as well as the correlation with the cancer treatments received
Disease and study population Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19
The study will be extended to all the centers of the Spanish Lung Cancer Group more than 170 centers and 500 professionals and it is expected that around 500 cases will be collected
The main objective of the study is to collect the safety and efficacy of the vaccine against SARS-CoV-2 in cancer patients as well as its potential interactions with antineoplastic therapies
The data collection will take place throughout the year 2021
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None